Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Free Cash Flow (2018 - 2025)

10x Genomics' Free Cash Flow history spans 8 years, with the latest figure at $39.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 512.09% year-over-year to $39.0 million; the TTM value through Dec 2025 reached $130.1 million, up 2371.16%, while the annual FY2025 figure was $130.1 million, 2371.16% up from the prior year.
  • Free Cash Flow for Q4 2025 was $39.0 million at 10x Genomics, down from $42.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $42.5 million in Q3 2025 and bottomed at -$82.8 million in Q4 2021.
  • The 5-year median for Free Cash Flow is -$11.1 million (2021), against an average of -$11.4 million.
  • The largest annual shift saw Free Cash Flow plummeted 697.23% in 2021 before it skyrocketed 684.1% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$82.8 million in 2021, then surged by 68.57% to -$26.0 million in 2022, then grew by 23.33% to -$19.9 million in 2023, then skyrocketed by 52.54% to -$9.5 million in 2024, then surged by 512.09% to $39.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Free Cash Flow are $39.0 million (Q4 2025), $42.5 million (Q3 2025), and $14.6 million (Q2 2025).